2025 International Congress

October 5-9, 2025. Honolulu, Hawaii.

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Concomitant Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis Versus Motoneuron Phenotype of PSP in Ukrainian Patient

Y. Trufanov, Y. Compta, M. Trishchynska, N. Khanenko, G. Chupryna, V. Sereda, A. Ovchynnykova (Kyiv, Ukraine)
Conjugal Parkinsonism

CK. Tan (Singapore, Singapore)
Connectome of Pathology Stages of Progressive Supranuclear Palsy

N. Vallenas, H. Tanaka, S. Lee, G. Kovacs, B. Couto (New York, USA)
Constructing a multicenter neuroimaging dataset to unveil structural brain alterations in GNAO1-related disorders

JD. Ortigoza-Escobar, J. Dominguez-Carral, J. Romagosa Pérez, A. Schteinschnaider, L. Soliani, D. Muñoz, M. Troncoso, MC. Miranda, JJ. Nieto, A. Camacho Salas, WG. Ludlam, K. Martemyanov, J. Muchart, CS. Stephan-Otto (Barcelona, Spain)
Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years

H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Floro, N. Abid, V. Tabar (New York, USA)
Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study

P. Lewitt, R. Hauser, D. Kremens, A. Formella, M. Grall, M. Joshi, P. Qin (Detroit, USA)
Continuous Subcutaneous Dopaminergic Stimulation: Exploring the impact of Foslevodopa/Foscarbidopa on Gait in Parkinson’s disease.

C. O'Keeffe, J. Inocentes, M. Bradley, A. Gallagher, F. Ruggieri, R. Walsh, T. Lynch, R. Reilly, C. Fearon (Dublin, Ireland)
Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease

M. Georgiades, D. Tsui, X. Chen, S. Bray, J. Qiu, S. Waller, L. Williams, S. Dal, T. Ong, A. Martin, H. Morales-Briceno, V. Fung (Sydney, Australia)
Continuous, Subcutaneous Apomorphine Infusion (CSAI) for PD: Development of a Phase IV routine practice study to capture the patient, care partner, and healthcare professional experience in the United States

M. Grall, A. Christiansen, N. Maskeri, S. Reyes, P. Qin, S. Isaacson (Rockville, USA)
Contribution of Dopamine Depletion, Cerebral Perfusion, and Cognition to Gait Dysfunction in Parkinson’s Disease

HK. Na, CW. Park, Y. Sun, JH. Lee, YY. Choi, SJ. Chung, YH. Sohn, CH. Lyoo, PH. Lee (Seodaemun-gu, Republic of Korea)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z